Catalyst Wire Dossier Catalyst Wire Dossier

Anti-EGFR monoclonal antibody

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-EGFR monoclonal antibody, covering 2026-03-03 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies [Phase 2]

See pricing